Open AccessJournal Article
Targeted therapy in radioiodine refractory thyroid cancer
7
TL;DR: The outstanding progress in the molecular basis of thyroid carcinoma offered the tool for the development of new drugs, mainly tyrosine-kinase inhibitor and inhibitors of proangiogenic factors, which are currently in phase II or III clinical trials with promising results (the so called targeted therapy).
read more
Abstract: The majority of differentiated thyroid carcinomas (DTCs) of follicular cell origin are cured with adequate surgical management and radioiodine therapy. Other thyroid malignancies such as medullary thyroid carcinoma (MTC) or poorly differentiated thyroid carcinomas frequently metastasize, precluding patients from a curative resection. Therapeutic options for these patients include additional surgery for resectable lesions, external radiotherapy and chemotherapy. The results of this approach is usually disappointing and the use of novel therapeutic approaches is needed. The outstanding progress in the molecular basis of thyroid carcinoma offered the tool for the development of new drugs, mainly tyrosine-kinase inhibitor and inhibitors of proangiogenic factors, which are currently in phase II or III clinical trials with promising results (the so called targeted therapy). This review will summarize the most relevant achievements in the field and will discuss the limit and perspective of the new compounds.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Nigel Fleeman,Rachel Houten,Adrian Bagust,Marty Richardson,Sophie Beale,Angela Boland,Yenal Dundar,Janette Greenhalgh,Juliet Hounsome,Rui V. Duarte,Aditya Shenoy +10 more
TL;DR: The feasibility of comparing lenvatinib with sorafenib via an indirect comparison would not be appropriate because of differences in trial and participant characteristics, risk profiles of the participants in the placebo arms and because the proportional hazard assumption was violated for five of the six survival outcomes available from the trials.
Bone Marrow Function After I-131 Therapy in Patients With Differentiated Thyroid Carcinoma
Hester T. Prinsen,Esther N. Klein Hesselink,Adrienne H. Brouwers,John T. M. Plukker,Wim J. Sluiter,Anouk N A van der Horst-Schrivers,Gustaaf W. van Imhoff,Thera P. Links +7 more
TL;DR: Posttreatment platelets and leukocytes were transiently decreased compared with pretreatment values in a general DTC population, implying that in most patients the clinical effects of bone marrow toxicity are limited.
Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence
Hendrieke C. Hoftijzer,Ellen Kapiteijn,T. C. Schneider,Guido C. Hovens,Hans Morreau,Hans Gelderblom,Johannes W. A. Smit +6 more
TL;DR: Conventional and new treatment modalities in differentiated advanced thyroid cancer are described, with the focus on kinase inhibitors.
Thyroid Cancer: The Evolution of Treatment Options
Hitoshi Noguchi
- 21 Mar 2012
TL;DR: The purpose of this chapter is to bridge the gap by presenting an historical overview of the various controversies in the field of thyroid cancer that shaped current knowledge and thereby assist the student in grasping the underlying structure beneath the vast amount of sometimes conflicting data.
References
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
10K
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Vandana Gupta-Abramson,Andrea B. Troxel,Anoma Nellore,Kanchan Puttaswamy,Maryann Redlinger,Kathy Ransone,Susan J. Mandel,Keith T. Flaherty,Laurie A. Loevner,Peter J. O'Dwyer,Marcia S. Brose +10 more
TL;DR: Sorafenib has clinically relevant antitumor activity in patients with metastatic, iodine-refractory thyroid carcinoma, with an overall clinical benefit rate of 77%, median PFS of 79 weeks, and an overall acceptable safety profile.
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos,Matthew D. Ringel,Michael V. Knopp,Nathan Hall,Mark A. King,Robert Stevens,Jiachao Liang,Paul E. Wakely,Vasyl Vasko,Motoyasu Saji,Jennifer Rittenberry,Lai Wei,Daria Arbogast,Minden Collamore,John J. Wright,Michael R. Grever,Manisha H. Shah +16 more
TL;DR: Sorafenib is reasonably well-tolerated therapy with clinical and biologic antitumor activity in metastatic PTC and four of 10 paired tumor biopsies from PTC patients showed a reduction in levels of vascular endothelial growth factor receptor phosphorylated, ERK phosphorylation, and in VEGF expression during sorafenIB therapy.
Motesanib diphosphate in progressive differentiated thyroid cancer.
Steven I. Sherman,Lori J. Wirth,Jean Pierre Droz,Michael Hofmann,Lars Bastholt,Renato G. Martins,Lisa Licitra,Michael Eschenberg,Yu Nien Sun,Todd Juan,Daniel E. Stepan,Martin Schlumberger +11 more
TL;DR: Motesanib diphosphate can induce partial responses in patients with advanced or metastatic differentiated thyroid cancer that is progressive and decrease in serum thyroglobulin concentration during treatment.